Kuang-Chi Technologies subsidiary signs 907 million yuan supermaterials product order

Corporate ActionPrice ActionProduct / Tech
โดย 数据宝·CN·Read original
Summary · why it matters

Kuang-Chi Technologies' wholly owned subsidiary Kuang-Chi Advanced Technology will deliver supermaterials structural products worth a total of 907 million yuan to three customers. That evening, several listed companies disclosed major contracts and capital operations: Zhejiang Construction Investment Group's subsidiary won a public housing development project bid of about 1.5 billion Hong Kong dollars, Xianghe Industrial signed a 178 million yuan railway fastener system components sales contract, Fulongma signed a 200 million yuan sanitation autonomous driving technology development contract with Huawei Cloud Computing, and Aidea Pharmaceutical plans a private placement to raise no more than 945 million yuan for the global clinical development of a novel HIV integrase inhibitor and other projects. Hengrui Pharmaceuticals repurchased 335,000 A-shares for the first time that day, paying 14.5036 million yuan. Longshen Rongfa's controlling subsidiary's marketing application for brexpiprazole oral dissolving film was not approved. In that day's Dragon-Tiger List, MetaX, one of the leading domestic GPU companies, saw the largest net institutional selling of 2.142 billion yuan, while its share price rose more than 14 percent; Ruifeng Advanced Materials saw the largest net institutional buying of 212 million yuan.

Impact on stocks 9

Others± Mixed · 9 stocks
Kuang Chi Technologies Co Ltd
002625
▲ PositiveDemandrelevance

Kuang-Chi Technologies' wholly owned subsidiary will deliver supermaterials structural products worth 907 million yuan to three customers.

Fujian Longma Envi Sanitation
603686
▲ PositiveDemandrelevance

Fulongma signed a 200 million yuan sanitation autonomous driving technology development contract with Huawei Cloud Computing.

Jiangsu Aidea Pharmaceutical Co Ltd
688488
▲ PositiveCapitalrelevance

Aidea Pharmaceutical plans a private placement to raise no more than 945 million yuan for global clinical development of a novel HIV integrase inhibitor and other projects.

Off-coverage companies 1

HuaweiPrivate± Mixed
relevance

© 2026 MarketDXNews